WILKES NSG 552 PSYCHOPHARMACOLOGY
EXAM 1 COMPREHENSIVE EXAMINATION TEST
2026
◉ Low potency antipsychotics. Answer: Low affinity to a receptor,
most likely to cause metabolic syndrome.
◉ Neuromalignant syndrome. Answer: A rare, life-threatening
reaction after exposure to neuroleptic drugs, caused by excessive
dopamine receptor blockage.
◉ Dantrolene. Answer: Medication administered for muscle
relaxation.
◉ Bromocriptine. Answer: Medication used to treat conditions like
Parkinson's disease.
◉ QTc interval. Answer: Measure of time between start of Q wave
and end of T wave in cardiac cycle (c = corrected).
◉ FGA side effect profile. Answer: Includes EPS, TD, dystonia,
hyperpyrexia, heat stroke, NMS, pneumonia, hypotension, HTN, QT
prolongation, torsade de pointes, arrhythmia, sudden death,
,hyponatremia, seizures, hepatic impairment, leukopenia,
neutropenia, agranulocytosis, cataracts, retinopathy, withdrawal sx if
abrupt D/C (long term use).
◉ SGA side effect profile. Answer: Includes suicidality, depression
exacerbation, EPS, TD, dystonia, NMS, hyper/hypothermia,
anaphylaxis, acute generalized exanthematous pustulosis, SJS, drug
reaction with eosinophilia and systemic symptoms, severe
hypotension, seizures, syncope, TIA, stroke, QT prolongation,
diabetes mellitus, hyperglycemia, hypothyroidism, pancreatitis,
rhabdomyolysis, agranulocytosis, leukopenia, neutropenia, cataracts,
severe dysphagia, priapism, intestinal obstruction.
◉ Ziprasidone. Answer: Antipsychotic medication likely to have the
least amount of weight gain.
◉ Haloperidol. Answer: Antipsychotic medication least likely to
result in metabolic syndrome.
◉ Aripiprazole, Asenapine, Clozapine, Quetiapine, Olanzapine.
Answer: Antipsychotic medications least likely to cause increased
prolactin.
◉ Haloperidol, Olanzapine, Aripiprazole. Answer: Antipsychotic
medications least likely to cause QT elongation.
, ◉ Clozapine, Quetiapine. Answer: Antipsychotic medications least
likely to cause EPS.
◉ Four steps to monitor for metabolic syndrome. Answer: 1) Obtain
Baseline -> weight, BMI, fasting glucose and lipids, BP, EKG; 2)
Recheck weight+BMI at 4 weeks, 8 weeks, 12 weeks, 6 months,
quarterly, and annually; 3) Check fasting glucose and lipids
biannually; 4) If metabolic syndrome is suspected then switch
agents, lower dose, and/or add metformin.
◉ ETOH use increases risk for TD. Answer: TRUE.
◉ Akasthesia. Answer: A state of agitation, distress, and restlessness
that is an occasional side-effect of antipsychotic and antidepressant
drugs.
◉ Dystonia. Answer: Involuntary muscle contraction that causes
repetitive or twisting movements.
◉ Psuedo-parkinsonism. Answer: AKA DRUG INDUCED
PARKINSONISM is a reversible condition that resembles
parkinsonism.
EXAM 1 COMPREHENSIVE EXAMINATION TEST
2026
◉ Low potency antipsychotics. Answer: Low affinity to a receptor,
most likely to cause metabolic syndrome.
◉ Neuromalignant syndrome. Answer: A rare, life-threatening
reaction after exposure to neuroleptic drugs, caused by excessive
dopamine receptor blockage.
◉ Dantrolene. Answer: Medication administered for muscle
relaxation.
◉ Bromocriptine. Answer: Medication used to treat conditions like
Parkinson's disease.
◉ QTc interval. Answer: Measure of time between start of Q wave
and end of T wave in cardiac cycle (c = corrected).
◉ FGA side effect profile. Answer: Includes EPS, TD, dystonia,
hyperpyrexia, heat stroke, NMS, pneumonia, hypotension, HTN, QT
prolongation, torsade de pointes, arrhythmia, sudden death,
,hyponatremia, seizures, hepatic impairment, leukopenia,
neutropenia, agranulocytosis, cataracts, retinopathy, withdrawal sx if
abrupt D/C (long term use).
◉ SGA side effect profile. Answer: Includes suicidality, depression
exacerbation, EPS, TD, dystonia, NMS, hyper/hypothermia,
anaphylaxis, acute generalized exanthematous pustulosis, SJS, drug
reaction with eosinophilia and systemic symptoms, severe
hypotension, seizures, syncope, TIA, stroke, QT prolongation,
diabetes mellitus, hyperglycemia, hypothyroidism, pancreatitis,
rhabdomyolysis, agranulocytosis, leukopenia, neutropenia, cataracts,
severe dysphagia, priapism, intestinal obstruction.
◉ Ziprasidone. Answer: Antipsychotic medication likely to have the
least amount of weight gain.
◉ Haloperidol. Answer: Antipsychotic medication least likely to
result in metabolic syndrome.
◉ Aripiprazole, Asenapine, Clozapine, Quetiapine, Olanzapine.
Answer: Antipsychotic medications least likely to cause increased
prolactin.
◉ Haloperidol, Olanzapine, Aripiprazole. Answer: Antipsychotic
medications least likely to cause QT elongation.
, ◉ Clozapine, Quetiapine. Answer: Antipsychotic medications least
likely to cause EPS.
◉ Four steps to monitor for metabolic syndrome. Answer: 1) Obtain
Baseline -> weight, BMI, fasting glucose and lipids, BP, EKG; 2)
Recheck weight+BMI at 4 weeks, 8 weeks, 12 weeks, 6 months,
quarterly, and annually; 3) Check fasting glucose and lipids
biannually; 4) If metabolic syndrome is suspected then switch
agents, lower dose, and/or add metformin.
◉ ETOH use increases risk for TD. Answer: TRUE.
◉ Akasthesia. Answer: A state of agitation, distress, and restlessness
that is an occasional side-effect of antipsychotic and antidepressant
drugs.
◉ Dystonia. Answer: Involuntary muscle contraction that causes
repetitive or twisting movements.
◉ Psuedo-parkinsonism. Answer: AKA DRUG INDUCED
PARKINSONISM is a reversible condition that resembles
parkinsonism.
